New York, June 29, 2026, 18:06 (EDT)
- Pfizer Inc. NYSE:PFE ticked up 0.4% to $24.37 late Monday. The S&P 500 gained 1.18% in regular trading.
- Pfizer’s ecnoglutide and Innovent Biologics Inc. HKG:1801 mazdutide both cleared an initial review in China for a spot on the country’s national medical insurance drug list, according to Reuters.
- Pfizer shares are at $24.37, putting the stock at roughly 8.4x the midpoint of its 2026 adjusted EPS target. The $0.43 per share quarterly dividend yields about 7.1% annualized.
Pfizer Inc. NYSE:PFE ticked up on Monday, rising after a move in China increased reimbursement for its GLP-1 offering, giving it another inroad into the market. Shares added 0.4% to $24.37 late in New York trading, but trailed a broader rally. The S&P 500 ended up 1.18% at 7,440.43, and the Nasdaq Composite jumped 2.07%.
| Market read-through | Latest price or level | Move |
|---|---|---|
| Pfizer Inc. NYSE:PFE | $24.37 | up 0.4% |
| Health Care Select Sector SPDR Fund (NYSEARCA:XLV) | $160.74 | up 0.2% |
| S&P 500 | 7,440.43 | up 1.18% |
It’s really about scale for investors. Reuters said sales of GLP-1 drugs on Alibaba NYSE:BABA and JD.com NASDAQ:JD sites hit around 1.4 billion yuan ($207 million) in Q1, using Jefferies numbers. That would be about $828 million a year through those e-commerce channels. Meanwhile, Pfizer’s annualized dividend payout based on $0.43 per share and 5.731 billion Q1 diluted shares comes to almost $9.9 billion.
This isn’t a full China market view. It skips public hospitals and some other channels. That explains why the shares didn’t move much after the single reimbursement shift. Even a fast China GLP-1 launch has to be big enough to register against Pfizer’s $139.7 billion market cap, its dividend load, and its 2026 revenue outlook of $59.5 billion to $62.5 billion.
| Pfizer at $24.37: by the numbers | Calculation | Result |
|---|---|---|
| 2026 adjusted EPS midpoint P/E | $24.37 / $2.90 | 8.4x |
| Dividend yield annualized | $1.72 / $24.37 | 7.1% |
| Dividend vs. EPS midpoint | $1.72 / $2.90 | 59% |
| Dividend run-rate per year | $1.72 × 5.731 bln shares | $9.9 bln |
China’s first round review is still important. Pfizer’s ecnoglutide and Innovent’s mazdutide both have approval in China for weight loss and type 2 diabetes. If they make it into the country’s national insurance drug list, more people could get access, but prices might also drop to public hospital levels.
| China GLP-1 item | Fresh fact | Stock read-through |
|---|---|---|
| Pfizer ecnoglutide | Cleared the initial medical-insurance review | Move clears one hurdle, but price questions still out there |
| Innovent mazdutide | Cleared the same review; Innovent stock jumped about 7% | China market gives more weight to home players |
| Novo Nordisk NYSE:NVO Ozempic | Put on China’s reimbursement list in 2022 | Class already had drugs on reimbursement |
| Eli Lilly and Co. NYSE:LLY Mounjaro | Listed this year for type 2 diabetes | Pfizer now joins bigger established GLP-1 names |
Linda Shu, who runs China healthcare research at HSBC Qianhai Securities, told Reuters she doesn’t see Pfizer or Innovent posing much of a competitive risk in diabetes. Shu said if price talks fail, a drug won’t get reimbursed the next year. An Innovent spokesperson told Reuters only diabetes use could be included for medical insurance coverage in China.
Pfizer NYSE:PFE posted a 5% rise in first-quarter revenue to $14.45 billion, but adjusted diluted EPS dropped 18% to $0.75. R&D spending was up 12% operationally, with most of the increase coming from oncology and obesity candidates. The company reported 22% operational growth in launched and acquired products.
That’s why the market is taking a tough view. Pfizer is trading more as an income play, not a pure growth bet. The board set a $0.43 dividend for the third quarter last week, its 351st consecutive payout, payable Sept. 1 to stockholders on record July 24. In May, Pfizer said it hadn’t done any share repurchases in 2026 and its forecast assumes no buybacks for this year.
The obesity pipeline is still in the future for Pfizer. The company’s first obesity drug from its $10 billion Metsera buy won’t hit the market before 2028 even if the trials work out, Reuters reported in May. RBC Capital’s Trung Huynh said after Pfizer’s Q1 release that the stock is “a catalyst story, not an earnings story.” Reuters
A Monday legal headline was less squarely about the equity side. Reuters said a group that won a court bid for FDA COVID-19 vaccine approval documents is now pressing a judge for over $867,000 in legal fees and costs. Pfizer wasn’t named as a defendant but joined the case to shield its sensitive business data.
Pfizer will next face the market on Aug. 4 during its Q2 2026 conference call, where it’s set to release quarterly results. Investors are also waiting for the outcome of China reimbursement discussions, expected by year-end.
